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Abstract
Histone deacetylases (HDAC) are key enzymes in the epigenetic control of gene expression. Recently, inhibitors of class I and
class II HDAC have been successfully employed for the treatment of different inflammatory diseases such as rheumatoid
arthritis, colitis, airway inflammation and asthma. So far, little is known so far about a similar therapeutic effect of inhibitors
specifically directed against sirtuins, the class III HDAC. In this study, we investigated the expression and localization of
endogenous sirtuins in primary human dermal microvascular endothelial cells (HDMEC), a cell type playing a key role in the
development and maintenance of skin inflammation. We then examined the biological activity of sirtinol, a specific sirtuin
inhibitor, in HDMEC response to pro-inflammatory cytokines. We found that, even though sirtinol treatment alone affected
only long-term cell proliferation, it diminishes HDMEC inflammatory responses to tumor necrosis factor (TNF)a and
interleukin (IL)-1b. In fact, sirtinol significantly reduced membrane expression of adhesion molecules in TNFa ˜- or IL-1b-
stimulated cells, as well as the amount of CXCL10 and CCL2 released by HDMEC following TNFa treatment. Notably, sirtinol
drastically decreased monocyte adhesion on activated HDMEC. Using selective inhibitors for Sirt1 and Sirt2, we showed a
predominant involvement of Sirt1 inhibition in the modulation of adhesion molecule expression and monocyte adhesion on
activated HDMEC. Finally, we demonstrated the in vivo expression of Sirt1 in the dermal vessels of normal and psoriatic skin.
Altogether, these findings indicated that sirtuins may represent a promising therapeutic target for the treatment of
inflammatory skin diseases characterized by a prominent microvessel involvement.
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Introduction
Sirtuins, the class III NAD
+-dependent deacetylases, are
emerging regulators of several biological processes [1]. Their
initially-investigated activity was as mediators of the increased life-
span that follows calorie restriction in yeast [2], but recent data
indicate their involvement in aging, genomic stability, tumorigen-
esis, and metabolic diseases [3]. In mammals, seven sirtuins have
been described, with Sirt1 being the closest homologue to the yeast
Sir2 [4]. Therefore, most studies have been focused on Sirt1
whereas the other six sirtuins have been less investigated. Sirt1 was
found to inhibit cellular senescence induced by DNA damage and
oxidative stress [5], and to increase upon caloric restriction or
nutrient starvation [6]. At the molecular level, Sirt1 plays a role in
transcriptional and post-transcriptional regulation of gene expres-
sion through deacetylation of histones and non-histone proteins,
and novel targets of Sirt1 are continuously discovered [1].
Regarding vascular biology, Sirt1 is a key mediator of angiogenic
signaling in postnatal neovascularization both in vitro and in
models of zebrafish and mouse [7]. Sirt1 inhibition induces a
premature senescence-like phenotype in cultured umbilical vein
endothelial cells (HUVEC), in parallel with increased p53
acetylation [8], and in porcine aortic endothelial cells, as a
consequence of the deregulation of the LKB1-AMPK pathway
[9]. Moreover, Sirt1 plays a role in regulating endothelial nitric
oxide and endothelium-dependent vascular tone by deacetylating
nitric oxide synthase [10].
Even though initially developed as anti-cancer agents, class I
and II HDAC inhibitors have shown therapeutic utility in the
treatment of chronic immune and inflammatory disorders such as
rheumatoid arthritis [11], colitis [12], airway inflammation and
asthma [13]. So far, little is known so far about a possible
therapeutic effect of inhibitors specifically directed against sirtuins,
but recent findings indicate that inhibition of Sirt1 attenuates
antigen-induced airway inflammation and hyperresponsiveness
[14].
Morphological and functional alterations of microvessels are
hallmark features of inflammatory disorders. In fact, microvascular
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24307endothelial cells are highly-specialized regulators of both tissue
homeostasis and pathological process of inflammation [15,16]. In
response to inflammatory cytokines, microvascular endothelial
cells become activated, display increased leakiness, secrete
additional inflammatory chemokines, enhance leukocyte chemo-
taxis and adhesiveness to vessel wall, thus favoring leukocyte
extravasation, distribution, and homing to the specific tissue.
Specific differences exist between endothelial cells of the
microvasculature and cells lining large blood vessels, and between
microvascular endothelial cells from different tissues, including
differences in secreted products, in cell adhesion molecule
expression, in the molecular response to cytokines [17,18,19,20].
Thus, evaluation of inflammation mechanisms in selected tissues
should be performed directly on tissue-derived microvascular
endothelial cells rather than on large vessel-derived endothelium.
In this study, we analyzed the expression and localization of
sirtuins in primary human dermal microvascular endothelial cells
(HDMEC), and underlined the effectiveness of sirtuin inhibition in
the modulation of flogistic responses of HDMEC activated with
pro-inflammatory cytokines.
Results
Sirtuin expression pattern
To analyze the mRNA expression pattern of the seven
mammalian sirtuins in HDMEC, semi-quantitative RT-PCR
analyses was performed and showed that Sirt5, Sirt2, and Sirt1
were highly expressed, followed by Sirt7 (Fig. 1A). A similar
pattern of sirtuin expression was present in HUVEC, even though
a higher amount of sirtuin-encoding mRNA was generally
detected, and two mitochondrial sirtuins [21], Sirt3 and Sirt4,
were slightly more expressed than Sirt7 (Fig. 1A). HDMEC sirtuin
expression pattern was cell-type specific, as it differed from those of
other skin cells (Data S1), such as keratinocytes, fibroblasts, and
melanocytes (Fig. S1A).
Protein expression of the four sirtuins more represented in
HDMEC at the RNA level was also analyzed (Fig. 1B). Protein
amount of the four sirtuins was similar between HDMEC and
HUVEC. Moreover, differently from mRNA, Sirt2 protein
amount was slightly higher in HDMEC compared to HUVEC,
probably reflecting a different posttranscriptional regulation. The
two known isoforms of Sirt2 and Sirt5 were distinguished, even if
their relative amount varied among cell extract preparations (see
Fig. 1B and Fig. S1B). The 50 kDa Sirt7 protein was also present,
barely detectable in endothelial cells compared to HeLa cells, used
as a positive control [22].
To investigate cellular localization of these four sirtuins,
confocal microscopy was performed on HDMEC. As expected,
Sirt1 was detected in the nucleus, whereas Sirt2 was equally
present in the cytoplasm and nucleus. Sirt5 was detected both in
mitochondria and nuclei, and Sirt7 co-localized in the nucleoli
[22,23] with the upstream binding transcription factor (UBF)
(Fig. 1C). We evaluated Sirt2 and Sirt5 localization also on
extracts prepared through differential cell lysis (Data S1) and
confirmed that these sirtuins were present in both the cytoplasmic
and nuclear compartments (Fig. S1B).
Effect of sirtinol on cell growth and histone acetylation in
HDMEC
Sirtinol, 2-[(2-Hydroxynaphthalen-1-ylmethylene)amino]-N-
(1-phenethyl)benzamide, is a selective inhibitor of sirtuin
enzymatic activity that does not affect class I or class II HDACs
[24,25]. As it was previously reported that sirtinol interferes with
HUVEC growth [7], we verified sirtinol effectiveness in our cell
type. HDMEC were treated for 18 hours with different
concentrations of the inhibitor. Fetal calf serum, as a prolifer-
ation stimulus, was then added and cells were cultured for 9
additional days (Data S1). Sirtinol treatment inhibited HDMEC
long-term proliferation in a dose-dependent manner, with the
concentrations of 5 and 10 mM reaching a significant level of
inhibition at 9-days culture (Fig. S2A). In the subsequent
experiments, a sirtinol dose of 10 mM was chosen. We next
investigated the effect of sirtinol on HDMEC viability by
analyzing apoptosis and necrosis. Measurement of cytoplasmic
histone-associated DNA fragments revealed that sirtinol alone
did not affect cell apoptosis or necrosis at 18 hours of treatment
(data not shown). We also analyzed the effect of sirtinol on
histone 3 (H3) and histone 4 (H4) total acetylation. In these
experiments, to obtain a sufficient amount of histone proteins
from the cell lysates to perform an enzyme-linked immunosor-
bent assay (ELISA), an immortalized human microvascular
endothelial cell line was used (Data S1). As shown in Fig. S2B,
sirtinol treatment resulted into increased acetylation of both H3
and H4. The effect of sirtinol on histone acetylation grade was
then confirmed by immunofluorescence on primary HDMEC.
As shown in Fig. S2C, deacetylation of H4 lysine 16 residue, a
preferential substrate for Sirt1 [8], was highly inhibited, and
deacetylation of H3 lysine 9 residue was also impaired, both
leading to augmented histone acetylation.
Sirtinol treatment regulates cellular responses to
inflammatory stimuli
T oa n a l y z et h ee f f e c to fs i r t i n o lo nH D M E Cr e s p o n s et o
inflammatory stimuli, HDMEC were sequentially treated with
sirtinol and/or with 10 ng/ml tumor necrosis factor (TNF)a or
interleukin (IL)-1b, two cytokines having a potent pro-inflam-
matory activity on endothelial cells [26]. After 5-hour or 24-hour
treatments, HDMEC were examined by flow cytometry (FACS)
for expression of inflammation-related adhesion molecules. We
found that sirtinol alone did not modify membrane expression of
the examined proteins but, after 5-hour treatment with TNFa,i t
slightly reduced expression of ICAM-1, VCAM-1, and E-selectin
(Fig. 2). After 24-hour stimulation with TNFa, sirtinol pretreat-
ment significantly reduced membrane expression of ICAM-1,
VCAM-1, and E-selectin, without affecting MHC class I (Fig. 3).
Upon stimulation with IL-1b for 5 hours in the presence of
sirtinol, a clear-cut down-regulation of ICAM-1, VCAM-1, and
E-selectin expression was observed (Fig. 2). After 24-hour
treatment with IL-1b, sirtinol led to a significant reduction of
ICAM-1, VCAM, and E-selectin membrane levels, although less
marked than those obtained with TNFa treatment (Fig. 3).
Again, MHC class I expression was not modified by sirtinol
pretreatment (Fig. 3).
Conditioned medium of HDMEC treated with sirtinol and with
TNFa or IL-1b was then examined by ELISA for vascular
endothelial growth factor-A (VEGF-A) and for inflammatory
chemokine secretion. In basal conditions, HDMEC did not secrete
detectable amounts of VEGF-A and sirtinol treatment, alone or in
combination with TNFa or IL-1b, did not induce any further
production of the growth factor (data not shown). CXCL10,
CXCL8, and CCL2 secretion was not significantly modified in
HDMEC treated with sirtinol, either in respect to basal condition
or compared with cells concurrently treated with IL-1b for
24 hours (Fig. 4A). However, sirtinol pretreatment significantly
inhibited the secretion of CXCL10 and CCL2, but not of CXCL8,
induced by a 24-hour treatment with TNFa (Fig. 4A).
Down-regulation of adhesion molecule or chemokine expression
observed in sirtinol- and TNFa- or IL-1b-treated HDMEC was
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particular of IL-1 receptor I and TNF receptor 1, since their
expression was not affected by sirtinol, as demonstrated by RT-
PCR analysis of untreated and 18-hour sirtinol-treated samples
(data not shown).
To investigate the biological significance of sirtinol-mediated
reduction of expression of cell surface immunomodulatory
molecules and of release of inflammatory chemokines potentially
involved in the recruitment of leukocytes during inflammation, a
monocyte adhesion assay on activated HDMEC was performed.
The U937 cell line was chosen for the initial studies, as it exhibits
many characteristics of primary monocytes and it has been widely
used as a model for blood-borne monocytes [27]. Very few
fluorescence-labelled U937 cells adhered to HDMEC over
2 hours in the absence of TNFa or IL-1b stimulus, regardless to
the previous exposure to sirtinol (Fig. 4B). On the other hand, after
HDMEC stimulation with the two inflammatory cytokines, the
number of adherent cells greatly increased and was dramatically
reduced when HDMEC were pretreated with sirtinol (Fig. 4B).
Adhesion assays on activated HDMEC were then repetead using
fresly isolated human primary monocytes, and gave comparable
results (Fig. 4B).
Figure 1. Sirtuin expression in endothelial cells. (A) Semi-quantitative RT-PCR of sirtuin expression. Bars refer to mRNA amounts relative to
GAPDH mRNA. Results are shown as the mean 6 s.d. of at least three experiments. (B) Western blotting of four sirtuins, indicated by arrows, the
molecular weights of which are given in kDa. A representative experiment is reported. Tubulin and GAPDH were used as loading controls. The
densitometric analysis of three different experiments is shown as the mean 6 s.d. HUVEC values for the first three sirtuins and HELA value for Sirt7
were used as reference and reported as 1 (C) Sirtuins were stained with the corresponding primary antibody (left panel). HDMEC were also
immunostained with a nuclear or a nucleolus marker (middle panels), or with a mitochondria marker (Sirt5, third panel from the left). Merged pictures
in the right panels. Each panel is a total projection of a confocal stack of images; bars = 20 mm.
doi:10.1371/journal.pone.0024307.g001
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Sirtinol inhibitory properties have been tested in vitro on human
Sirt1 and Sirt2 [25]. Therefore, in an attempt to identify which
sirtuin was mainly involved in the modulation of HDMEC
inflammation responses, we used the two inhibitors, 6-chloro-
2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide or EX527 [28],
and 2-cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-
2-propenamide or AGK2 [29], selectively affecting Sirt1 and
Sirt2, respectively. FACS analysis showed that Sirt1 blocking
reduced ICAM-1 and VCAM expression induced by both TNFa
and IL-1b after the 5-hour-treatment (Fig. 5A) and, to a lesser
extent, after the 24-hour one (data not shown). On the other hand,
inhibition of Sirt2 did not decrease the expression of ICAM-1 and
VCAM after treatment with IL1b and TNFa (Fig. 5A). As no anti-
inflammatory effect was detected following AGK2 treatment, we
verified that the selected dose of AGK2 was effectively inhibiting
Sirt2 in HDMEC. We analyzed tubulin acetylation as it represents
the main target of Sirt2 deacetylase activity (Data S1) and found a
2.5 time increase in tubulin acetylation following AGK2 treatment
(Fig. S1C).
Finally, to prove that the observed EX527-mediated reduction
of cell surface adhesion molecules was sufficient to sustain an anti-
inflammatory effect in HDMEC, the monocyte adhesion assay was
repeated. As shown in Fig. 5B, after HDMEC stimulation with the
two inflammatory cytokines, the number of adherent monocytes,
either U937 cell line or primary human monocytes, was
significantly reduced when HDMEC were pretreated with EX527.
Sirt1 is expressed in HDMEC in vivo
To evaluate whether Sirt1 could represent a possible therapeu-
tic target for the treatment of inflammatory skin diseases
characterized by a prominent microvessel involvement, we
analyzed Sirt1 expression in vivo in the microvessels of normal
and psoriatic skin. As shown in Fig. 6A, dermal vessels clearly
expressed Sirt1 in the endothelial cell nucleus. An analogous, even
though less prominent staining, was also observed in the dermal
vessels of psoriatic skin. To further investigate this down-
modulation of Sirt1 expression in psoriatic HDMEC, we treated
HDMEC in vitro for 24 hours with different cytokines, i.e. TNFa,
IL-1b, interferon (IFN)-c, IL-17, or VEGF-A, all highly present in
the psoriatic skin lesions. Then, we analyzed by immunoblotting
Sirt1 protein expression and observed that IFNc, IL-17, and
VEGF-A slightly, but not significantly, reduced Sirt1 amount in
HDMEC (Fig. 6B).
Discussion
Systematic investigation of sirtuin expression is an important
preliminary step to study the selective role of class III HDAC. So
far, this kind of studies has been mainly performed on transformed
cells, and little is known about sirtuin expression in normal human
cell types. Moreover, cell localization studies have been carried out
through overexpression of exogenous sirtuins [30]. One sirtuin at
the time was often examined, even though it has been reported
that overexpression of a single exogenous sirtuin can interfere with
localization of another one in a specific cellular compartment [21].
In the present work, we firstly evaluated the expression of
endogenous sirtuins in HDMEC, a normal primary human cell
type. Considering the mRNA production, Sirt1, Sirt2, Sirt5, and
Sirt7 are expressed at higher levels as compared to Sirt3, Sirt4,
and Sirt6. A similar but not entirely overlapping pattern could be
observed in HUVEC, suggesting differences between micro and
macrovascular endothelial cells, and between different skin cell
types, such as keratinocytes, fibroblasts, and melanocytes. Protein
expression and localization of four sirtuins were then evaluated,
showing the expected nuclear localization for Sirt1 and the
reported presence of Sirt7 in the nucleolar compartment.
Interestingly, confocal microscopy and western blotting analysis
of different cellular compartments detected Sirt2 both in the
cytoplasm and in the nucleus, and Sirt5 both in mithocondria and
in the nucleus. Sirt2 was previously reported to shuttle from the
cytoplasmic to the nuclear compartment and vice versa, whereas
Sirt5 localization in the nucleus was not previously shown. This
data might reflect the existence of an additional nuclear target for
the deacetylase activity of Sirt5 in HDMEC.
Then, to investigate the relevance of targeting sirtuins for the
treatment of skin inflammatory diseases, we used the selective
inhibitor sirtinol. As previously reported for HUVEC, we found
that sirtinol reduced HDMEC long-term proliferation. Sirtinol
treatment alone did not affect cell apoptosis and necrosis, showing
absence of a significant basal toxicity at the used doses.
Nevertheless, sirtinol treatment greatly inhibited histone deacety-
lation in HDMEC.
Importantly, we found that sirtinol short-term effects on
HDMEC were mainly directed towards the down-modulation of
the inflammatory response. Inhibitors of class I and II HDAC
trigger both pro- and anti-inflammatory effects depending on the
targeted cell type [31,32]. Specifically regarding endothelial cells,
treatment of HUVEC with trichostatin-A inhibited TNFa-
mediated induction of VCAM-1, and effectively blocked
VCAM-1-dependent leukocyte adhesion [33]. Likewise, we
showed here that sirtinol pre-treatment reduces adhesion molecule
expression and chemokine secretion induced by two inflammatory
agents and block monocyte adhesion to activated endothelial cells.
Our results clearly indicate that the overall final outcome of
sirtinol treatment on HDMEC is the neutralization of exogenous-
ly-added inflammatory stimuli.
Using more selective inhibitors, we also showed that Sirt1
inhibition is largely involved in the anti-inflammatory action of
sirtinol. In apparent contrast with our findings, Sirt1 was
previously reported to suppress inflammation in several tissues
[34,35,36]. In tumor cells, Sirt1 acts as a negative regulator of NF-
kB, that represents a master regulator of inflammatory signalling
[37]. However, Sirt1 knockout mice do not display the same
inflammatory phenotype of mice expressing a constitutive active
form of p65 NF-kB subunit [38], indicating that Sirt1 does not
modulate the totality of NF-kB-dependent genes. Moreover,
trichostatin-A, that exerts an anti-inflammatory effect on endo-
thelial cells, was reported to potentiate NF-kB-dependent
transcription in tumor cells [37]. Clearly, more complex regulatory
processes are present in the onset of inflammation and are
expected to be cell-type specific [32].
In addition, our present data and the indication of another
study on the anti-inflammatory effect of sirtinol [14], strongly
suggest that a broad inhibition of sirtuins could act differently from
the selective interference of one single enzyme. Indeed, when we
Figure 2. Expression of adhesion molecules in sirtinol-treated HDMEC after a 5-hour stimulation. HDMEC were analyzed for ICAM-1,
VCAM-1, E-selectin, and MHC Class I by flow cytometry after 18-hour treatment with medium alone (no add) or 10 mM sirtinol, followed by a 5-hour
stimulation with 10 ng/ml of the indicated cytokines. Dotted lines represent staining with matched isotype Ig. The x-axis and the y-axis indicate the
relative cell number and mean fluorescence intensity, respectively. Data are representative of at least ten different experiments with similar results.
doi:10.1371/journal.pone.0024307.g002
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same anti-inflammatory effect obtained with sirtinol, clearly
indicating the existence of a multifaceted sirtuin network acting
in response to the inflammatory stimuli.
Finally, we showed that Sirt1 was expressed in vivo in normal
and psoriatic human skin. Interestingly, Sirt1 expression was
reduced in the nuclei of the psoriatic dermal vessels. This could be
due to the effect of cytokines, such as the lymphokine IFN-c,
Figure 3. Expression of adhesion molecules in sirtinol-treated HDMEC after a 24-hour stimulation. HDMEC were analyzed for ICAM-1,
VCAM-1, E-selectin, and MHC Class I expression by flow cytometry after treatment with medium alone (no add) or sirtinol, followed by a 24-hour
stimulation with the indicated cytokines. Dotted lines represent staining with matched isotype Ig. The x-axis and the y-axis indicate the relative cell
number and mean fluorescence intensity, respectively. Data are representative of at least twelve different experiments with similar results.
doi:10.1371/journal.pone.0024307.g003
Figure 4. Chemokine secretion and monocyte adhesion in sirtinol-treated HDMEC. (A) HDMEC conditioned medium was analyzed by
ELISA after treatment with medium alone (no add) or sirtinol, followed by stimulation with the indicated cytokines. Results are the mean of at least
three independent experiments and are given in ng/10
6 cells 6 s.d; *p#0.01, **p#0.001, T-student test. (B) Fluorescence-labelled U937 cells or
primary monocytes were plated on HDMEC pretreated or not (no add) with sirtinol, and exposed or not (CTR) to TNFa or IL-1b. Adherent cells were
quantified as the mean number of fluorescent cells present in 10 randomly selected fields for each condition. Pictures of a representative experiment
are shown in the left panels, bar = 50 mm. Data are expressed as the mean of three different experiments 6 s.d (panel below), **p#0.005, T-student
test.
doi:10.1371/journal.pone.0024307.g004
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reduced also in the basal keratinocytes of psoriatic lesions, with
IFN-c inhibiting Sirt1 expression [39]. However, treatment of
HDMEC in vitro with IFN-c, as well as with IL-17 or VEGF-A,
slightly and not significantly reduced Sirt1 protein expression,
indicating that the observed down-modulation of Sirt1 expression
observed in vivo could not be due to a direct action of a single
inflammatory cytokine. In addition, the endogenous down-
modulation of Sirt1 expression in psoriatic skin per se is not
sufficient to suppress local inflammatory responses and a further
reduction of Sirt1 could be beneficial in a therapeutic treatment.
In conclusion, our study highlights previously unrecognized
anti-inflammatory properties of sirtinol in dermal endothelial cells,
and suggests that sirtuins could represent potential targets for the
treatment of skin inflammation.
Materials and Methods
Cell culture and reagents
HDMEC were isolated from foreskin of 4 different donors as
previously described [40], cultured in EGM-2MV (Lonza, Basel,
Switzerland), and used at passage 4 to 8. HUVEC were isolated
from 3 different donors, cultured as previously described [41], and
used up to passage 4. To obtain primary human monocytes,
peripheral blood mononuclear cells (PBMC) were separated from
healthy donor whole blood by density gradient centrifugation over
Lymphoprep (Nycomed-Pharmacia, Oslo, Norway). After exten-
sive washing, PBMC were separated by immunomagnetic positive
selection into CD14
+ population by using magnetic beads
according to the manufacturer’s protocol (Miltenyi Biotec,
Gladbach, Germany) and resulting in a 90% to 98% monocyte
purity. U937 cell line (American Type Culture Collection, ATCC,
LGC Standards, UK) was maintained in RPMI-1640 medium
(Life Technologies, Grand Island, NY), supplemented with 10%
fetal calf serum (Lonza) and 2 mM/l L-glutamine (Life Technol-
ogies). HeLa cell line (ATCC) was grown and maintained in
DMEM medium (Life Technologies) supplemented with 10% fetal
calf serum and 2 mM/l L-glutamine.
Recombinant human TNFa, IL-1b, VEGF-A, IFNc and IL-17
were purchased from R&D Systems (Minneapolis, MN). Sirtinol
was prepared according to reported procedures [25]. EX527 and
AGK2 were purchased from Tocris Bioscience, Bristol, UK.
RT-PCR
Cells were processed for RNA extraction utilizing the RNeasy
Plus Mini Kit (Qiagen, Hilden, Germany) according to supplier’s
instructions. Reverse transcription was performed with Superscript
III RT (Invitrogen, Carlsbad, CA) starting from 1 mg of total
RNA. Primer sequences were as follows: Sirt1 (GenBank
NM_012238; oligonucleotide forward 405-428 bp, reverse 563-
586 bp); Sirt2 (GenBank NM_012237; oligonucleotide forward
438–461 bp, reverse 699–722 bp); Sirt3 (GenBank NM_012239;
oligonucleotide forward 290–313 bp, reverse 527–550 bp); Sirt4
(GenBank NM_012240; oligonucleotide forward 414–437 bp,
reverse 565–588 bp); Sirt5 (GenBank NM_012241; oligonucleo-
tide forward 365–388 bp, reverse 507–530 bp); Sirt6 (GenBank
NM_016539; oligonucleotide forward 301–324 bp, reverse 487–
510 bp); Sirt7 (GenBank NM_016538; oligonucleotide forward
605–628 bp, reverse 849–872 bp). Amplification conditions were:
denaturation 95uC, 30 sec; annealing 55uC, 1 min; extension
68uC,1 min. [a-32P]dATP was added to the reaction (0.04 mCi/
ml); 32 cycles were performed to obtain sirtuin amplicons, whereas
24 cycles were used for GAPDH amplicon. PCR products were
separated on a 6% polyacrylamide gel and quantitatively analyzed
in a Typhoon Trio imager system using the IMAGE QUANT
version 5.0 software (GE Healthcare, Amersham, UK). PCR
products were also separated on a 2% agarose gel, extracted from
the gel with the Gel Extraction kit (Qiagen) and sequenced.
Western blotting
Confluent HDMEC were lysed in a buffer containing 20 mM
Tris-HCl, 150 mM NaCl, 1% Triton. Cell lysates were centri-
fuged, and supernatants directly evaluated for total protein
amount with the BioRad Protein Assay (BioRad, Hercules, CA).
Equal quantity of total proteins were separated by 6 or 12% SDS-
gel electrophoresis and transferred onto a nitrocellulose membrane
(Hybond-ECL, GE Healthcare). Protein detection was performed
using the following antibodies: Sirt1 (H-300) and Sirt2 (A-5) (Santa
Cruz Biotechnologies, Santa Cruz, CA), Sirt5 (Enzo Life Science,
Plymouth Meeting, PA), Sirt7 (Sigma, Saint Louis, MO), a-tubulin
(Calbiochem, Darmstadt, Germany), GAPDH (Santa Cruz
Biotechnologies), and a chemiluminescence detection system (GE
Healthcare). Relative intensity of signals was quantified using a
GS-710 densitometer (Bio-Rad). In selected experiments,
HDMEC were treated with 10 ng/ml TNFa, 10 ng/ml IL-1b,
30 ng/ml VEGF-A, 500 U/ml IFNc, or 20 ng/ml IL-17 for
24 hours. Equal quantity of total protein lysates were separated by
4–15% SDS-gradient gel electrophoresis and transferred onto a
nitrocellulose membrane. Protein detection and loading normal-
ization were performed using the anti-Sirt1 antibody H-300 (Santa
Cruz Biotechnologies) and the anti-a-tubulin antibody (Calbio-
chem), respectively.
Immunofluorescence and confocal analysis
HDMEC were seeded on coverslips, synchronized by serum
deprivation, and allowed to reach subconfluence. For mitochon-
dria staining, cells were washed with 1x phosphate buffer (PBS)
and incubated with 40 nM MitoTrackerH Red (CMXRos, Life
Technologies) for 45 min at 37uC. Cells were then fixed with 3%
paraformaldehyde/PBS, permeabilized with 0.1% Triton X-100,
and blocked for 30 min with 1% BSA, followed by incubation with
primary antibody overnight at 4uC. Antibodies were as follows:
Sirt1 (D739, Cell Signaling Technology, Beverly, MA), Sirt2
(Epitomics, Burlingame, CA), Sirt5 (Enzo Life Science and
Abnova, Taipei City, Taiwan), Sirt7 [22], UBF (F-9, Santa Cruz
Biotechnologies). After washing in 1x PBS, cells were incubated
with the appropriate secondary antibodies 1 hour at room
temperature. Nuclei were visualized by adding 1 mM TO-
PROH-3 iodide (Life Technologies) for 10 min at room temper-
ature. For tissue studies, four-mm-thick paraformaldehyde-fixed,
paraffin-embedded human skin sections were used, and specimens
Figure 5. Adhesion molecule expression and monocyte adhesion in EX527- or AGK2-treated HDMEC. (A) HDMEC were analyzed for
ICAM-1 and VCAM-1 expression by flow cytometry after treatment with medium alone (no add), EX527, or AGK2, followed by a 5-hour stimulation
with the indicated cytokines. Dotted lines represent staining with matched isotype Ig. The x-axis and the y-axis indicate the relative cell number and
mean fluorescence intensity, respectively. Data are representative of three different experiments which gave similar results. (B) Fluorescence-labelled
U937 cells or primary monocytes were plated on HDMEC pretreated or not (no add) with EX527, and exposed or not (CTR) to TNFa or IL-1b. Adherent
cells were quantified as the mean number of fluorescent cells present in 10 randomly selected fields for each condition. Data are expressed as the
mean of three different experiments 6 s.d; *p#0.05, **p#0.005, T-student test.
doi:10.1371/journal.pone.0024307.g005
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described [42]. Tissue was permeabilized with 0.1% Triton X-
100. An anti-Sirt1 polyclonal antibody (E104, Abcam) was used, at
a dilution of 1:100 and incubated over night at +4uC. The signal
was amplified with the TSA biotin system (Perkin-Elmer Life
Science, Boston, MA) following the manufacturer’s instructions.
To identify endothelial cells, an anti-human PECAM/CD31
polyclonal antibody (JC/70A, Abcam) was used, diluted 1:25 and
incubated for 1 hour at 37uC. After washing, sections were
incubated with the appropriate secondary antibodies 1 hour at
room temperature. Negative controls were performed by omitting
the primary antibody. Coverslips were mounted and slides
analyzed using a Zeiss LSM 510 meta-confocal microscope (Zeiss,
Oberkochen, Germany).
FACS analysis
HDMEC were cultured to subconfluence, starved of serum and
growth factors for 6 hours, treated with 10 mM sirtinol for
18 hours, and stimulated with 10 ng/ml IL-1b or TNFa for 5
or 24 hours. In selected experiments, serum-starved HDMEC
were treated with 1 mM EX527 or 10 mM AGK2 for 18 hours
before stimulation with IL-1b or TNFa. Expression of membrane
ICAM-1, VCAM, E-selectin, and MHC class I was evaluated after
5 and 24 hours using fluorescein isothiocyanate (FITC)-conjugat-
ed anti-ICAM-1 (clone 84H10, Immunotech, Marseille, France),
anti-MHC class I (clone G46 2.6, BD Pharmingen, Franklin
Lakes, NJ), allophycocyanin (APC)-conjugated anti-human
VCAM-1 (clone 51-10C9, BD Pharmingen) and anti-human E-
selectin (clone 68-5H11, BD Pharmingen). In control samples,
staining was performed using isotype-matched control antibodies.
Morphological features and parameters of cells treated with
sirtinol and/or cytokines were similar. Cells were analyzed with a
FACScan equipped with Cell Quest software (Becton Dickinson,
Mountain View, CA).
ELISA
Cell-free supernatants from unstimulated or stimulated
HDMEC were tested for VEGF-A amount, using the Quantikine
kit (R&D Systems), and for CXCL10, CCL2, and CXCL8
content, using OptEIA kits (BD Pharmingen), following manufac-
turer’s protocol. Plates were analyzed in a Microplate reader 3550-
UV (BioRad). HDMEC supernatants were assayed in triplicate for
each condition.
Monocyte adhesion to HDMEC
U937 cell line or primary human monocytes were fluorescently
labeled with 29,79-bis-(2-carboxyethyl)-5-(and-6)-carboxy-fluores-
cein acetoxymethyl ester (BCECF-AM, Molecular Probes, Eu-
gene, OR) as described [43]. Briefly, cells (1610
7 cells/5 ml) were
incubated with 5 mM/l BCECF-AM in RPMI-1640 medium for
30 min at 37uC. Cells were then washed three times with 1x PBS
to remove excess dye and resuspended at a density of 5610
5 cells/
ml. HDMEC were cultured to confluence on coverslips and
treated at 37uC with 10 mM sirtinol or with 1 mM EX527 for
18 hours. HDMEC were then stimulated with 10 ng/ml IL-1b or
TNFa for additional 24 hours. BCECF-labeled U937 and
BCECF-labeled primary monocytes (2.5610
5 cells/well) were
Figure 6. Sirt1 expression in skin microvessels. (A) Sirt1 was
stained with the primary antibody (left panels), and endothelial cells
w e r ep u ti ne v i d e n c ew i t hac o - s t a i n i n gf o rt h eP E C A M / C D 3 1
transmembrane adhesion molecule (middle panels). Merged pictures
are in the right panels. Each panel is a total projection of a confocal
stack of images; bars = 20 mm. (B) HDMEC were treated with the
indicated cytokines and the cell lysates were analyzed by immunoblot-
ting with an anti-Sirt1 antibody. An antibody against tubulin was used
as a loading control. A representative experiment is reported and the
densitometric analysis of at least three different experiments is shown
as the mean 6 s.d.
doi:10.1371/journal.pone.0024307.g006
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37uC. Non-adherent cells were removed by washing with 1x PBS.
Cells were fixed with 3% paraformaldehyde/PBS, washed in 1x
PBS, and mounted on slides. At least ten randomly selected fields
for each treatment were recorded with a digital camera (AxioCam
MRc5, Zeiss) and fluorescent cells were counted.
Supporting Information
Figure S1 Sirtuin RNA and protein expression in skin
cell types and effect of sirtuin inhibition on tubulin
acetylation. (A) Semi-quantitative RT-PCR analysis of sirtuin
expression in normal primary human fibroblasts (FB), keratino-
cytes (K), and melanocytes (Mel). Bars refer to sirtuin mRNA
amounts relative to GAPDH mRNA. Results are shown as the
mean 6 s.d. of at least three experiments performed on cells
isolated from different individuals. (B) Sirt2 and Sirt5 subcellular
localization was analyzed by Western blotting in HDMEC whole
extract (WE), nuclear (N), and cytoplasmic (C) fraction that
comprises also mitochondria. Sirt2 and Sirt5 polypeptides are
indicated by arrows. The molecular weight of the sirtuin isoforms
is given in kDa. Lamin A/C is a nuclear protein, tubulin is present
in the cytoplasm, and Cox4 is a mitochondria specific protein, all
used to verify protein separation in the different cell compart-
ments. A representative experiment is shown. (C). Western blotting
analysis of acetyl-tubulin (upper panel) or total tubulin (lower
panel) in endothelial cells not treated or treated for 18 hours with
the selective Sirt1 inhibitor (EX527) or the specific Sirt2 inhibitor
(AGK2). Molecular weight of acetyl-tubulin is given in kDa. A
representative experiment is reported. The densitometric analysis
of two different experiments is shown as the mean 6 s.d.
(TIF)
Figure S2 Effect of sirtinol on HDMEC proliferation
and histone acetylation. (A) HDMEC were treated with
different concentrations of sirtinol or left untreated (no add). Cell
proliferation was measured, at the indicated days after stimulus, by
cell staining with crystal violet and determination of the A540.
Results are shown as the mean 6 s.d. of at least three independent
experiments; *p#0.005, ** p#0.01. (B) HMEC cells were treated
with 10 mM sirtinol (sirtinol) or left untreated (no add). Total
acetylation level of H3 and H4 was assessed by determining A450
as described in Data S1. Absorbance in non specific wells is also
reported (blank). Results are expressed as the mean of two different
experiments 6 s.d. (C) HDMEC were treated with 10 mM sirtinol
(Sirtinol) or left untreated (No add). Cells were stained with
antibodies against H4 acetylated lysine 16 (H4K16acetyl, left
panel) and H3 acetylated lysine 9 (H3K9acetyl, right panel). Dapi
was used to counter stain nuclei in all experiment. Bar= 10 mm.
(TIF)
Data S1 Methods for human skin primary cell and
HMEC cell line culture. Methods for preparation of nuclear
and cytoplasmic fractions from a HDMEC whole cell lysate and
subsequent western blotting assay. Methods for analysis of
HDMEC proliferation, and of HMEC and HDMEC histone or
tubulin acetylation status.
(DOC)
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